Volume 28, Issue 3 pp. 325-337
Full Paper

Fragment-Based QSAR and Molecular Modeling Studies on a Series of Discodermolide Analogs as Microtubule-Stabilizing Anticancer Agents

Lívia B. Salum

Lívia B. Salum

Laboratório de Química Medicinal e Computacional, Centro de Biotecnologia Molecular Estrutural, Instituto de Física de São Carlos, Universidade de São Paulo, Av. Trabalhador São-Carlense 400, 13560-970 São Carlos-SP, Brazil, Fax: +55-16-3373-9881

Search for more papers by this author
Luiz C. Dias

Luiz C. Dias

Instituto de Química, Universidade Estadual de Campinas, UNICAMP C. P. 6154, 13084-971 Campinas-SP, Brazil

Search for more papers by this author
Adriano D. Andricopulo

Adriano D. Andricopulo

Laboratório de Química Medicinal e Computacional, Centro de Biotecnologia Molecular Estrutural, Instituto de Física de São Carlos, Universidade de São Paulo, Av. Trabalhador São-Carlense 400, 13560-970 São Carlos-SP, Brazil, Fax: +55-16-3373-9881

Search for more papers by this author
First published: 06 March 2009
Citations: 13

Abstract

Inhibition of microtubule function is an attractive rational approach to anticancer therapy. Although taxanes are the most prominent among the microtubule-stabilizers, their clinical toxicity, poor pharmacokinetic properties, and resistance have stimulated the search for new antitumor agents having the same mechanism of action. Discodermolide is an example of nontaxane natural product that has the same mechanism of action, demonstrating superior antitumor efficacy and therapeutic index. The extraordinary chemical and biological properties have qualified discodermolide as a lead structure for the design of novel anticancer agents with optimized therapeutic properties. In the present work, we have employed a specialized fragment-based method to develop robust quantitative structure–activity relationship models for a series of synthetic discodermolide analogs. The generated molecular recognition patterns were combined with three-dimensional molecular modeling studies as a fundamental step on the path to understanding the molecular basis of drug–receptor interactions within this important series of potent antitumoral agents.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.